

UNIVERSITY OF MARYLAND
DEPARTMENT OF RADIATION ONCOLOGY

SCHEDULE OF
PRESENTATIONS AND ACTIVITIES

**AI & EI: CARING FOR THE PATIENT
IN A WIRELESS WORLD**



**2022 Annual Meeting
San Antonio, Texas
October 23-26**

SUNDAY, OCTOBER 23 PRESENTATIONS

8:05 AM

Conditional survival of patients with prostate cancer undergoing external-beam radiotherapy on RTOG 0126 and 0415

Alexander GS, Krc RF, Assif JW, Sun K, Molitoris JK, Rana Z, Tran PT, Bentzen SM, Mishra MV

Quick pitch oral, abstract 1003

Session QP01, Rm 304

8:10 AM

Evaluating heterogeneity of hippocampal avoidant whole brain radiotherapy (HA-WBRT) treatment effect on neurocognitive function (NCF): Secondary analysis of NRG-CC001

Cherng HRR, Sun K, Bentzen SM, Gondi V, Mehta MP, Mishra MV

Oral, abstract 102

Session SS02, Rm 217

8:15 AM

Conditional survival probabilities in recurrent prostate cancer (PCa) patients receiving radiation \pm antiandrogen therapy: Secondary analysis of a randomized clinical trial

Assif JW, Alexander GS, Krc RF, Sun K, Molitoris JK, Rana ZH, Tran PT, Bentzen SM, Mishra MV

Quick pitch oral, abstract 1004

Session QP01, Rm 304

8:20 AM

Prostate-specific membrane antigen PET response associates with metastasis-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer

Sutera P, Deek M, Cem Guler O, Hurmuz P, Reyhan M, Rowe S, Hrinivich WE, **Ren L**, Song DY, Kiess A, Oymak E, Pienta K, Pomper M, Feng FY, Ozyigit G, **Tran PT**, Phillips RM, Onal C

Quick pitch oral, abstract 1005

Session QP01, Rm 304

8:30 AM

Risk factors for progression and toxicity after preoperative radiosurgery for resected brain metastases: A PROPS-BM multicenter cohort study

Prabhu RS, Akinyelu T, Vaslow ZK, Matsui J, Dan T, **Mishra MV**, Murphy ES, Boyles S, Perlow HK, Palmer JD, Patel TR, Wardak Z, Woodworth G, Ksenzovsky A, Yang K, Chao ST, Asher AL, Burri SH

Oral, abstract 108

Session SS02, Rm 217

4:45 PM

Biologically effective dose as a predictor of radiosurgery treatment outcomes for pulmonary metastases

Allen AJ, LaBella D, Waters MR, Kowalchuk RO, Kersh R

Poster Q&A, abstract 2898

Session PQA01, Exhibit hall 1

4:45 PM

The Impact of Body Mass Index and Residence in Food Priority Areas on Patterns-of-Care and Cancer Outcomes in Patients with Stage III Non-Small Cell Lung Cancer

Savla B, Hamza M, Markan K, Yacubovich D, Cobbs S, Petrovska L, Scilla K, Burrows W, Mehra R, Miller RC, Rolfo C, **Mohindra P, Vyfhuis M**

Poster Q&A, abstract 2802

Session PQA01, Exhibit hall 1

4:45 PM

Factors that influence a woman's decision to enroll in breast cancer clinical trials – implications on how to improve minority enrollment and retention

Markan U, DeCesaris C, **Nichols EM, McAvoy SA, Ruff S, Cheston S, Mohindra P**, Oswald P, **Vyfhuis M**

Poster Q&A, abstract 2299

Session PQA01, Exhibit hall 1

MONDAY, OCTOBER 24 PRESENTATIONS

8:00 AM

Long-term outcomes and genetic predictors of response to metastasis directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials

Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Lumen N, Phillips R, Delrue L, Verbeke S, De Man K, Song DY, Paller CJ, Joniau S, De Meerleer G, Lotan TL, Berlin A, Siva S, Ost P, **Tran PT**

Oral, abstract 133

Session SS07, Rm 008

10:45 AM

Single fraction vs. fractionated preoperative radiosurgery for resected brain metastases: A PROPS-BM multicenter cohort study

Prabhu RS, Akinyelu T, Vaslow ZK, Matsui J, Dan T, **Mishra MV**, Murphy ES, Boyles S, Perlow HK, Palmer JD, Patel TR, Wardak Z, Woodworth G, Ksendzovsky A, Yang K, Chao St, Asher AL, Burri SH

Poster Q&A, abstract 2136

Session PQA02, Exhibit hall 1

10:45 AM

The impact of racial disparities on molecular features, treatments rendered, and clinical outcomes for patients with glioma

Savla B, Waghmarae S, Yau J, **Cohen J**, **Sun K**, **Bentzen SM**, **Mossahebi S**, **Kwok Y**, **Regine WF**, **Mishra MV**

Poster Q&A, abstract 2172

Session PQA02, Exhibit hall 1

1:30 PM

Prostate cancer risk stratification in NRG Oncology phase III randomized trials using multi-modal deep learning with digital histopathology.

Tward JD, Zhang J, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Huang H-C, Schaeffer EM, Morgan TM, Monson JM, Campbell HA, Wallace JA, Ferguson MJ, Bahary J-P, Sandler HM, Spratt DE, Rodgers JP, Feng FY, **Tran PT**

Oral, plenary, abstract 2

Session PL01, Stars at Night Ballroom plenary

1:30 PM

NRG RTOG 1005: A phase III trial of hypo fractionated whole breast irradiation with concurrent boost versus conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer

Vicini FA, Winter K, Freedman GM, Arthur DW, Hayman JA, Rosenstein BS, **Bentzen SM**, Li A, Lyons J, Tomberlin JK, Seaward SA, **Cheston S**, Coster J, Anderson BM, Perera FE, Poppe MM, Petersen IA, Bazan JG Jr, Moughan J, White JR

Oral, plenary, abstract 1

Session PL01, Stars at Night Ballroom plenary

MONDAY, OCTOBER 24 PRESENTATIONS (CONT.)

3:00 PM

Clinical outcomes in patients receiving pencil beam proton re-irradiation for new or locoregionally recurrent breast cancer

Bazyar S, Assif J, Ruff SE, Molitoris JK, McAvoy SA, Mishra MV, Nichols EM

Poster Q&A, abstract 2060

Session PQA03, Exhibit hall 1

3:30 PM

Phase II randomized study of salvage radiation therapy (SRT) plus enzalutamide or blinded placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA trial

Tran PT, Lowe K, Wang H, Tsai h-L, Song DT, Hung AY, Hearn JWD, Miller S, Lotan T, DeWeese TL, Orton M, DeVille C, Liauw S, Heath EI, Greco S, Desai NB, Spratt DE, Feng F, Beer TM, Antonarkis ES

Oral, abstract 159

Session SS11, Rm 214

5:00 PM

FLASH effects induced by kV x-rays in a murine skin model

Miles D, Sforza D, Siddiqui I, Wong J, **Tran PT**, Rezaee M

Poster Q&A, abstract 3131

Session PQA04, Exhibit hall 1

5:00 PM

Modeling complex data sets of radiation dose-response data as impacted by multiple critical variables (developmental status, chemotherapy, other risk factors)

Bentzen SM

Panel session 12, Rm 108

TUESDAY, OCTOBER 25 PRESENTATIONS

8:00 AM

Imaging for response assessment

Cao Y, moderator

Session SS16, Rm 006

12:45 PM

Biology may be king, but selection is still queen: Crushing stubborn B-cell lymphomas

Mohindra P, moderator

Session SS18, Rm 214

12:45 PM

Incorporating the patient voice: A session focused on PROs and survivorship

Mishra MV, moderator

Session SS17, Rm 007 C/D

12:45 PM

Initial report on liver reirradiation with proton beam therapy after 90Y transarterial chemoembolization

Rao M, Becker SJ, Vedam S, Guerrero M, Rana Z, Kunaprayoon D, Molitoris JK

Poster Q&A, abstract 2398

Session PQA05, Exhibit hall 1

TUESDAY, OCTOBER 25, PRESENTATIONS (CONT.)

12:45 PM

Multi-vendor environment in the clinic: What works, what doesn't, and what next

Ren L, moderator

Session EDU19, Rm 206

12:55 PM

Evaluating the utility of EQ5D-5L in patients with brain metastases: Secondary analysis of NRG-CC001

Cherng HRR, Qu MX, Zafari Z, Gondi V, Mehta MP, **Mishra MV**

Oral, abstract 189

Session SS02, Rm 007

2:30 PM

Toxicity analysis of patients with prostate cancer treated with 3D-conformal compared to intensity modulated radiotherapy: Secondary analysis of RTOG 0126 and RTOG 0415

Krc RF, **Assif JW**, **Alexander GS**, **Sun K**, **Molitoris JK**, **Rana ZH**, **Tran PT**, **Bentzen SM**, **Mishra MV**

Poster Q&A, abstract 2508

Session PQA06, Exhibit hall 1

4:00 PM

Clinical implementation and translation of AI in radiation oncology: Challenges, pitfalls, and promises

Ren L, moderator

Session EDU25, Rm 214

4:00 PM

AI for image-guided radiation therapy (IGRT): Advances and applications

Ren L

Session EDU25, Rm 214

4:00 PM

Automatic dose prescription for radiotherapy of brain metastases using two-path three-dimensional CNN

Cao Y, **Kunaprayoon D**, **Xu J**, **Ren L**

Poster Q&A, abstract 2209

Session PQA07, Exhibit hall 1

5:15 PM

Radiation and cancer biology

Tran PT, moderator

Session QP18, Rm 303

5:15 PM

Risk of cerebrovascular events among childhood and adolescent patients receiving cranial radiotherapy: A PENTEC normal tissue outcomes comprehensive review

Waxer J, Wong K, **Modiri A**, Charpentier A-M, Moiseenko V, Ronckers C, Raddei P, Constine L, Sprow G, Tamrazi B, MacDonald S, Olch A

Poster Q&A, abstract 3083

Session PQA08, Exhibit hall 1

WEDNESDAY, OCTOBER 26 PRESENTATIONS

8:10 AM

Role of WNT pathway mutations within oligometastatic castration-sensitive prostate cancer

Sutera P, Deek MP, Van der Eecken K, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, **Mishra MV, Rana Z, Molitoris JK, Ferris M**, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, **Tran PT**

Quick pitch oral, abstract 1110

Session QP19, Rm 304

12:30 PM

Changes in CT Hounsfield values of pericardium months after radiotherapy as surrogates for later major cardiotoxicity

Modiri A, Koduri A, **Savla B**, Ahmady A, Marter J, **Vicente E**, **Sawant A**, Jeudy J, **Mohindra P**

Poster Q&A, abstract 3263

Session PQA10, Exhibit hall 1

UNIVERSITY OF MARYLAND DEPARTMENT OF RADIATION ONCOLOGY WELCOME DINNER RECEPTION

Sunday, October 23

6:30–9:30 PM CDT

Boudro's Firewheel Room

205 N. Presa Street at Charles Court

San Antonio, TX

SPECIAL EVENT INDUCTION OF CLASS OF 2022 ASTRO FELLOWS

Tuesday, October 25

9:15 AM CDT

Stars at Night Ballroom

William F. Regine, MD, will be inducted as an ASTRO Fellow

ASTRO KEYNOTE ADDRESSES

Monday, October 24, 9:15 AM

Ruha Benjamin, PhD

Race to the future? Reimagining the default settings of technology and society

Keynote 01, Stars at Night Ballroom

Tuesday, October 25, 9:15 AM

Richard Deming, MD

Above and beyond cancer: Optimal living in survivorship

Keynote 02, Stars at Night Ballroom